

Leading on Biosimilars

2017 AAM Biosimilars Council Conference



MONDAY, SEPTEMBER 11, 2017

3:00 p.m. – 5:00 p.m. **Biosimilars Council Board of Directors Meeting**

TUESDAY, SEPTEMBER 12, 2017 – CONFERENCE DAY 1

7:30 a.m. – 8:30 a.m. **Networking Breakfast**

8:30 a.m. – 8:45 a.m. **Biosimilars Council Chair Welcome**
Bruce Leicher

General Counsel, Senior Vice President and Secretary
Momenta Pharmaceuticals, Inc.

8:45 a.m. – 9:15 a.m. **AAM CEO Welcome**
Chester (Chip) Davis, Jr., J.D.
President and CEO, AAM

9:15 a.m. – 10:00 a.m. **FDA Keynote**
Leah Christl, Ph.D. (Invited)
Associate Director, Therapeutic Biologics and Biosimilars Team, FDA

10:00 a.m. – 10:30 a.m. **Networking Refreshment Break**

10:30 a.m. – 12:00 p.m. **Market Access**

12:00 p.m. – 1:15 p.m. **Luncheon**

1:15 p.m. – 2:15 p.m. **Biosimilars: Delivering in Europe**
Adrian van den Hoven
Director General, Medicines for Europe

- 2:15 p.m. – 3:15 p.m. **The Promise of Biosimilars: How Patient Advocates are Educating on the Role of Biosimilars in Patient Care**
- 3:15 p.m. – 3:30 p.m. **Networking Refreshment Break**
- 3:30 p.m. – 4:15 p.m. **Investing in Biosimilars: Wall Street Outlook**
Eric Percher
Director, Equity Research, Barclays Capital
- 4:15 p.m. – 6:15 p.m. **Networking Reception**

WEDNESDAY, SEPTEMBER 13, 2017 - CONFERENCE DAY 2

- 8:00 a.m. – 9:00 a.m. **Networking Breakfast**
- 9:00 a.m. – 9:45 a.m. **FDA Commissioner Keynote**
Scott Gottlieb, M.D. (Invited)
Commissioner of Food and Drugs, FDA
- 9:45 a.m. – 10:45 a.m. **Biosimilars at the Bar: Legal Issues**
Chad A. Landmon, J.D.
Partner, Axinn, Veltrop & Harkrider LLP
- 10:45 a.m. – 11:15 a.m. **Networking Refreshment Break**
- 11:15 a.m. – 12:15 p.m. **Lessons Learned from the FDA Approval Process**
- 12:15 p.m. – 1:30 p.m. **Luncheon**
- 1:30 p.m. – 2:15 p.m. **Interchangeability – What is Next?**
- 2:15 p.m. – 3:30 p.m. **Biosimilars Discussion with Industry Leaders**
- 3:30 p.m. – 3:45 p.m. **Closing Remarks**
Bruce Leicher
General Counsel, Senior Vice President and Secretary
Momenta Pharmaceuticals, Inc.
- 3:45 p.m. **Conference Concludes**